Operating Expenses Summary of Masimo Corporation

Masimo Corporation's latest annual operating expenses in 2023 was 867 Million USD , down -1.13% from previous year.
Masimo Corporation's latest quarterly operating expenses in 2024 Q3 was 233.1 Million USD , up 2.91% from previous quarter.
Masimo Corporation reported a annual operating expenses of 848.8 Million USD in annual operating expenses 2022, up 59.39% from previous year.
Masimo Corporation reported a annual operating expenses of 532.52 Million USD in annual operating expenses 2021, up 9.19% from previous year.
Masimo Corporation reported a quarterly operating expenses of 226.5 Million USD for 2024 Q2, up 9.05% from previous quarter.
Masimo Corporation reported a quarterly operating expenses of 207.7 Million USD for 2024 Q1, up 5.01% from previous quarter.

Annual Operating Expenses Chart of Masimo Corporation (2023 - 1998)

Historical Annual Operating Expenses of Masimo Corporation (2023 - 1998)

Year	Operating Expenses	Operating Expenses Growth
2023	867 Million USD	-1.13%
2022	848.8 Million USD	59.39%
2021	532.52 Million USD	9.19%
2020	487.71 Million USD	19.55%
2019	407.95 Million USD	11.33%
2018	366.42 Million USD	8.49%
2017	337.73 Million USD	7.89%
2016	313.02 Million USD	1.19%
2015	309.34 Million USD	3.95%
2014	297.59 Million USD	9.77%
2013	271.1 Million USD	12.48%
2012	241.02 Million USD	16.09%
2011	207.61 Million USD	15.75%
2010	179.36 Million USD	7.68%
2009	166.57 Million USD	13.88%
2008	146.27 Million USD	26.39%
2007	115.73 Million USD	179.14%
2006	-146.23 Million USD	-374.01%
2005	53.36 Million USD	0.0%
2004	- USD	-100.0%
2003	30.75 Million USD	52.85%
2002	20.12 Million USD	0.0%
1999	13.79 Million USD	97.14%
1998	7 Million USD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q3	233.1 Million USD	2.91%
2024 Q2	226.5 Million USD	9.05%
2024 Q1	207.7 Million USD	5.01%
2023 Q2	191.9 Million USD	-22.24%
2023 Q1	246.8 Million USD	2.79%
2023 FY	839.2 Million USD	-1.13%
2023 Q4	197.8 Million USD	-2.37%
2023 Q3	202.6 Million USD	5.58%
2022 Q3	227.7 Million USD	-3.56%
2022 Q2	236.1 Million USD	62.81%
2022 Q1	145.01 Million USD	5.48%
2022 Q4	240.1 Million USD	5.45%
2022 FY	848.8 Million USD	59.39%
2021 FY	532.52 Million USD	9.19%
2021 Q1	131.21 Million USD	7.52%
2021 Q2	127.77 Million USD	-2.62%
2021 Q3	136.05 Million USD	6.48%
2021 Q4	137.48 Million USD	1.05%
2020 Q2	129.33 Million USD	10.43%
2020 Q1	117.11 Million USD	11.15%
2020 Q3	119.22 Million USD	-7.82%
2020 Q4	122.03 Million USD	2.35%
2020 FY	487.71 Million USD	19.55%
2019 Q3	104.63 Million USD	2.25%
2019 Q1	95.61 Million USD	1.18%
2019 Q2	102.33 Million USD	7.02%
2019 FY	407.95 Million USD	11.33%
2019 Q4	105.36 Million USD	0.7%
2018 Q4	94.5 Million USD	2.59%
2018 FY	366.42 Million USD	8.49%
2018 Q3	92.11 Million USD	1.74%
2018 Q1	89.77 Million USD	-5.04%
2018 Q2	90.53 Million USD	0.85%
2017 FY	337.73 Million USD	7.89%
2017 Q4	94.54 Million USD	17.17%
2017 Q3	80.69 Million USD	-1.08%
2017 Q2	81.56 Million USD	0.78%
2017 Q1	80.93 Million USD	-3.56%
2016 Q3	73.51 Million USD	-6.59%
2016 Q2	78.7 Million USD	2.38%
2016 Q1	76.87 Million USD	-8.98%
2016 Q4	83.92 Million USD	14.16%
2016 FY	313.02 Million USD	1.19%
2015 Q3	74.09 Million USD	-1.29%
2015 FY	309.34 Million USD	3.95%
2015 Q4	84.46 Million USD	14.0%
2015 Q2	75.06 Million USD	-0.88%
2015 Q1	75.72 Million USD	-1.02%
2014 Q2	74.69 Million USD	6.52%
2014 Q3	76.27 Million USD	2.12%
2014 Q4	76.51 Million USD	0.31%
2014 FY	297.59 Million USD	9.77%
2014 Q1	70.11 Million USD	0.35%
2013 Q3	66.73 Million USD	-1.93%
2013 FY	271.1 Million USD	12.48%
2013 Q1	66.44 Million USD	2.36%
2013 Q2	68.05 Million USD	2.43%
2013 Q4	69.87 Million USD	4.7%
2012 Q4	64.9 Million USD	7.5%
2012 Q2	58.75 Million USD	3.13%
2012 Q1	56.97 Million USD	6.4%
2012 Q3	60.38 Million USD	2.76%
2012 FY	241.02 Million USD	16.09%
2011 Q2	53.11 Million USD	3.26%
2011 Q3	49.5 Million USD	-6.8%
2011 Q4	53.54 Million USD	8.17%
2011 Q1	51.44 Million USD	-2.09%
2011 FY	207.61 Million USD	15.75%
2010 Q4	52.53 Million USD	7.72%
2010 Q1	28.75 Million USD	-35.34%
2010 FY	179.36 Million USD	7.68%
2010 Q2	49.29 Million USD	71.44%
2010 Q3	48.77 Million USD	-1.06%
2009 Q4	44.46 Million USD	7.4%
2009 Q1	40.66 Million USD	5.84%
2009 Q2	40.04 Million USD	-1.51%
2009 Q3	41.4 Million USD	3.39%
2009 FY	166.57 Million USD	13.88%
2008 Q3	35.23 Million USD	-3.8%
2008 Q4	38.41 Million USD	9.04%
2008 FY	146.27 Million USD	26.39%
2008 Q2	36.62 Million USD	1.74%
2008 Q1	35.99 Million USD	10.01%
2007 Q3	28.64 Million USD	4.15%
2007 Q4	32.71 Million USD	14.23%
2007 Q1	26.86 Million USD	-68.24%
2007 FY	115.73 Million USD	179.14%
2007 Q2	27.5 Million USD	2.37%
2006 Q1	- USD	100.0%
2006 FY	-146.23 Million USD	-374.01%
2006 Q3	- USD	0.0%
2006 Q4	84.59 Million USD	0.0%
2006 Q2	- USD	0.0%
2005 Q1	- USD	0.0%
2005 Q3	- USD	0.0%
2005 FY	53.36 Million USD	0.0%
2005 Q4	-96.08 Million USD	0.0%
2005 Q2	- USD	0.0%
2004 FY	- USD	-100.0%
2003 FY	30.75 Million USD	52.85%
2002 FY	20.12 Million USD	0.0%
1999 Q3	2.9 Million USD	0.0%
1999 Q4	4.6 Million USD	58.62%
1999 FY	13.79 Million USD	97.14%
1998 FY	7 Million USD	0.0%

Peer Operating Expenses Comparison of Masimo Corporation

Name	Operating Expenses	Operating Expenses Difference
Akoya Biosciences, Inc.	104.27 Million USD	-731.495%
AngioDynamics, Inc.	252.41 Million USD	-243.481%
AtriCure, Inc.	327.05 Million USD	-165.095%
Avinger, Inc.	18.63 Million USD	-4551.787%
Azenta, Inc.	336.26 Million USD	-157.832%
BioLife Solutions, Inc.	117.57 Million USD	-637.389%
The Cooper Companies, Inc.	1.82 Billion USD	52.488%
Daxor Corporation	1.28 Million USD	-67607.134%
Ekso Bionics Holdings, Inc.	24.19 Million USD	-3483.978%
Femasys Inc.	15.2 Million USD	-5603.829%
GlucoTrack, Inc.	7.1 Million USD	-12104.392%
Harvard Bioscience, Inc.	58.58 Million USD	-1380.002%
Hologic, Inc.	1.34 Billion USD	35.549%
ICU Medical, Inc.	717.04 Million USD	-20.912%
Intuitive Surgical, Inc.	2.96 Billion USD	70.736%
KORU Medical Systems, Inc.	26.1 Million USD	-3220.838%
LeMaitre Vascular, Inc.	90.33 Million USD	-859.74%
Innovative Eyewear, Inc.	-119.32 Thousand USD	726662.697%
Innovative Eyewear, Inc.	-119.32 Thousand USD	726662.697%
Microbot Medical Inc.	9.85 Million USD	-8697.565%
Meihua International Medical Technologies Co., Ltd.	18.42 Million USD	-4606.824%
Merit Medical Systems, Inc.	459.92 Million USD	-88.508%
Nephros, Inc.	9.78 Million USD	-8761.406%
NovoCure Limited	613.92 Million USD	-41.222%
NEXGEL, Inc.	4.09 Million USD	-21066.992%
NEXGEL, Inc.	4.09 Million USD	-21066.992%
Singular Genomics Systems, Inc.	102.24 Million USD	-747.98%
OraSure Technologies, Inc.	125.34 Million USD	-591.707%
Pro-Dex, Inc.	7.37 Million USD	-11651.152%
Pulse Biosciences, Inc.	43.57 Million USD	-1889.719%
Predictive Oncology Inc.	15.22 Million USD	-5592.887%
Precision Optics Corporation, Inc.	8.52 Million USD	-10073.537%
QuidelOrtho Corporation	1.35 Billion USD	36.029%
Repligen Corporation	261.12 Million USD	-232.027%
Sanara MedTech Inc.	61.12 Million USD	-1318.354%
STAAR Surgical Company	224.55 Million USD	-286.099%
Sharps Technology, Inc.	10.12 Million USD	-8461.568%
Utah Medical Products, Inc.	13.26 Million USD	-6437.968%
DENTSPLY SIRONA Inc.	1.79 Billion USD	51.672%
Jin Medical International Ltd.	3.91 Million USD	-22031.055%

Global Stocks Search

Masimo Corporation (MASI)

Operating Expenses Summary of Masimo Corporation

Annual Operating Expenses Chart of Masimo Corporation (2023 - 1998)

Historical Annual Operating Expenses of Masimo Corporation (2023 - 1998)

Peer Operating Expenses Comparison of Masimo Corporation